



SDI Review Form 1.6

Journal Name:	Ophthalmology Research: An international Journal
Manuscript Number:	2014_OR_10573
Title of the Manuscript:	<u>ROCK INHIBITORS: FUTURE OF ANTI-GLAUCOMA MEDICATION???</u>
Type of the Article	Minireview Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<u>Compulsory</u> REVISION comments		
<u>Minor</u> REVISION comments	Betaxololl, Tafluprost and other medications should be added in page 2 lines 33-35 Line 92 after et al put a “,”	Changes incorporated. Instead of mentioning all the drugs, only one drug has been mentioned in each group to maintain uniformity.
<u>Optional/General</u> comments	The authors should add the theoretical effect on human IOP, in other word which should be the IOP reduction? Are the drug company happy of this result or they looking for a better association?	Effect of ROCK inhibitors on IOP in human eyes has not yet been published although the company sites do show significant lowering of IOP from baseline (AMAKEM). However, in past the molecule SN 1656 was studied for its IP lowering effect but its trial has been now discontinued. Hence, it could not be mentioned in the article.